Clinical Trials
Clinical trials are an integral component of health care delivery at NSLHD.
Most existing medical interventions for diseases and conditions — including cancer, heart disease, hypertension and asthma — have been developed as a results of rigorous clinical trials, and ongoing support of trials is essential to the development of new interventions. Our commitment to clinical trials is highlighted by both the widespread distribution of trials across the district – trials occur at all our sites and facilities – and in the breadth disciplines involved. We established the Clinical Trials Reference Group, which reports to the Research Advisory Committee, to facilitate and grow the number of high quality clinical trials across NSLHD, to foster capacity and capability and to grow our visibility and participation in clinical trials. In 2020, the Clinical Trials Reference Group, in conjunction with NSLHD research support staff, delivered a number of projects designed to support our trials, and reduce administrative delays and burden for participants and staff.
Proportion of clinical trials with governance approval within 15 days (Jul-Dec 2020)
100%
Proportion of clinical trials receiving ethics approval within 45 days (Jul-Dec 2020)
100%
A key initiative for 2021 will be the growth of consumers involved in clinical trials and the development of research. We are indebted to patients and their carers who take part in our trials and studies. To ensure more trials are available to the community, we are developing a clinical trials section on the NSLHD website. Another focus will be the planning and delivery of a clinical trials management system, with the support of the Ministry of Health, which will further enable trials capacity across the district.
10
RESEARCH ANNUAL REPORT 2020
Made with FlippingBook - professional solution for displaying marketing and sales documents online